Cingulate (CING) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 May, 2026Executive summary
Annual Meeting scheduled for July 9, 2026, to be held virtually, with voting on key proposals including director election, auditor ratification, equity plan amendment, and potential adjournment.
Board recommends voting FOR all proposals: election of Jeff Hargroves as Class II director, ratification of KPMG LLP as auditor, amendment to the 2021 Omnibus Equity Incentive Plan, and adjournment if needed.
Proxy materials and annual report are available online, with voting accessible by mail, phone, or internet.
Voting matters and shareholder proposals
Proposals include: electing Jeff Hargroves as Class II director (term to 2029), ratifying KPMG LLP as auditor for 2026, amending the equity plan to add 625,000 shares, and approving adjournment if necessary.
Board unanimously recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by January 29, 2027, and director nominations between March 11 and April 10, 2027.
Board of directors and corporate governance
Board to be reduced from seven to five members after the meeting; Jeff Hargroves nominated as Class II director.
Board divided into three classes with staggered terms; independent directors meet regularly in executive session.
Falcon Creek Capital Advisor LLC retains rights to designate up to two directors, subject to ownership thresholds.
Committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board leadership structure reviewed periodically; currently, John A. Roberts serves as Chairman.
Latest events from Cingulate
- Key votes include director election, auditor ratification, and expanding the equity plan.CING
Proxy filing29 May 2026 - Board recommends approval of director election, auditor ratification, and equity plan amendment.CING
Proxy filing19 May 2026 - Q1 2026 net loss rose to $9.3M as cash climbed to $25.9M ahead of FDA review.CING
Q1 202614 May 2026 - CTX-1301 aims to disrupt the ADHD market with once-daily efficacy and strong clinical results.CING
Corporate presentation14 Apr 2026 - Advancing once-daily ADHD and anxiety drugs with $12M raised, but faces going concern risk.CING
Registration filing14 Apr 2026 - Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026